Epidermal growth factor-like protein 8 (EGFL8)

Epidermal growth factor-like protein 8 (EGFL8) is a member of the EGF-like domain family, a group of proteins containing EGF-like motifs which mediate protein-protein interactions and participate in diverse physiological functions[1]. EGFL8 has a conserved domain organization with an EMI domain and two EGF-like domains, including a calcium-binding subtype, and is predicted to be a secreted protein[1][5]. It is broadly expressed in various tissues, notably in the thymus, lymph nodes, testis, ovary, epithelial, and digestive tissues in mice[1]. EGFL8 exerts negative regulatory roles in mouse thymic epithelial cells and thymocytes, influencing proliferation, growth, and differentiation, and modulating genes related to immune and cell cycle pathways[5]. There is little published evidence for its involvement as a therapeutic target or for any drugs that act directly on EGFL8. Its precise molecular function and relevance in human disease remain subjects of ongoing research[1][5]. - EGFL8 is not a receptor or classical therapeutic target at this time and there are no known drugs or mechanisms of action specific to this protein[1][5]. - No safety concerns, biomarkers, or known roles in major human diseases have been established. - The full canonical name is “Epidermal growth factor-like protein 8”; EGFL8 is the standard abbreviation. - There is no evidence that the target is misspelled, incorrect, or not a molecular entity. EGFL8 is a validated protein-coding gene/protein in human and mouse[1][3][5].

Other names

C6orf8NG3UNQ8752/PRO29920Vascular endothelial statin-2VE-statin-2epidermal growth factor-like protein 8EGF-like protein 8